Main Article Content

Muhammad Ejaz
Sanobar Gull
Huma Umbreen
Farhana Noureen
Syeda Amber Hameed
Qudratullah Kalwar
Reema Bughio
Muhammad Arif Rizwan
Junaid Farooq
Habibullah Janyaro
I Made Dwi Mertha Adnyana


CUL7, LIHC, Metastasis, Prognosis


The investigation focused on exploring the role of CUL7 genes in Liver Hepatocellular Carcinoma (LIHC) development and progression. Utilizing the UALCAN database, a significant up-regulation of CUL7 expression was observed in LIHC tissues, suggesting its potential involvement in the development of LIHC. Subsequent analysis across various clinical parameters revealed consistent up-regulation of CUL7 expression in LIHC, regardless of cancer stage, patient gender, age, or racial background. Furthermore, promoter methylation analysis indicated hypermethylation of the CUL7 promoter in LIHC samples compared to normal controls, implying potential epigenetic dysregulation of CUL7 in LIHC pathogenesis. Notably, differences in promoter methylation levels were observed across different cancer stages, patient genders, ages, and racial groups, highlighting the complex relationship between CUL7 promoter methylation and various clinical parameters in LIHC. Additionally, survival analysis demonstrated a significant association between CUL7 expression levels and patient overall survival, with high CUL7 expression correlating with shorter survival rates in LIHC patients. However, mutational analysis using the cBioPortal platform did not reveal significant mutations in CUL7 in LIHC samples. Overall, these findings shed light on the potential role of CUL7 as a biomarker and therapeutic target in LIHC management, emphasizing its clinical significance in prognostic assessment and personalized treatment strategies.


Abstract 75 | PDF Downloads 27


[1] Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C and Stuart JM. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013; 45: 1113-1120.
[2] Hameed Y and Ejaz S. TP53 lacks tetramerization and N-terminal domains due to novel inactivating mutations detected in leukemia patients. Journal of Cancer Research and Therapeutics 2021; 17: 931-937.
[3] Khan M and Hameed Y. Discovery of novel six genes-based cervical cancer-associated biomarkers that are capable to break the heterogeneity barrier and applicable at the global level. Journal of Cancer Research and Therapeutics 2023;
[4] Ahmad M, Khan M, Asif R, Sial N, Abid U, Shamim T, Hameed Z, Iqbal MJ, Sarfraz U and Saeed H. Expression characteristics and significant diagnostic and prognostic values of ANLN in human cancers. International Journal of General Medicine 2022; 1957-1972.
[5] Zhou Y, Li Y, Zhou T, Zheng J, Li S and Li HB. Dietary Natural Products for Prevention and Treatment of Liver Cancer. Nutrients 2016; 8: 156.
[6] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
[7] Yasir M, Nawaz A, Ghazanfar S, Okla M, Chaudhary A, Al WH, Ajmal M, AbdElgawad H, Ahmad Z and Abbas F. Anti-bacterial activity of essential oils against multidrug-resistant foodborne pathogens isolated from raw milk. Brazilian Journal of Biology 2022; 84: e259449.
[8] Usman M, Hameed Y and Ahmad M. Does human papillomavirus cause human colorectal cancer? Applying Bradford Hill criteria postulates. ecancermedicalscience 2020; 14:
[9] Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA and Bray F. Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastroenterology 2020; 159: 335-349 e315.
[10] Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL, Anderson RN, Henley SJ, Kohler BA, Penberthy L, Feuer EJ and Weir HK. Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. J Natl Cancer Inst 2017; 109:
[11] Xu W, Li H, Hameed Y, Abdel-Maksoud MA, Almutairi SM, Mubarak A, Aufy M, Alturaiki W, Alshalani AJ and Mahmoud AM. Elucidating the clinical and immunological value of m6A regulator-mediated methylation modification patterns in adrenocortical carcinoma. Oncology Research 2023; 31: 819.
[12] Usman M and Hameed Y. GNB1, a novel diagnostic and prognostic potential biomarker of head and neck and liver hepatocellular carcinoma. Journal of Cancer Research and Therapeutics 2023;
[13] Usman M, Hameed Y and Ahmad M. Does epstein–barr virus participate in the development of breast cancer? A brief and critical review with molecular evidences. Biomedical and Biotechnology Research Journal (BBRJ) 2020; 4: 285-292.
[14] Hameed Y. Decoding the significant diagnostic and prognostic importance of maternal embryonic leucine zipper kinase in human cancers through deep integrative analyses. Journal of Cancer Research and Therapeutics 2023; 19: 1852-1864.
[15] Zhou H and Song T. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma. Biosci Trends 2021; 15: 155-160.
[16] Dong Y, Wu X, Xu C, Hameed Y, Abdel-Maksoud MA, Almanaa TN, Kotob MH, Al-Qahtani WH, Mahmoud AM and Cho WC. Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures. Aging 2024; 16: 2591-2616.
[17] Hu H, Umair M, Khan SA, Sani AI, Iqbal S, Khalid F, Sultan R, Abdel-Maksoud MA, Mubarak A and Dawoud TM. CDCA8, a mitosis-related gene, as a prospective pan-cancer biomarker: implications for survival prognosis and oncogenic immunology. American Journal of Translational Research 2024; 16: 432.
[18] Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, Khin MW and Koo WH. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009; 10: 1111-1118.
[19] Kimhofer T, Fye H, Taylor-Robinson S, Thursz M and Holmes E. Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review. Br J Cancer 2015; 112: 1141-1156.
[20] Sukowati CH, El-Khobar KE, Ie SI, Anfuso B, Muljono DH and Tiribelli C. Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. World J Gastroenterol 2016; 22: 1497-1512.
[21] Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, Hiddingh L, Roberge S, Koppel C, Lauwers GY, Zhu AX, Jain RK and Duda DG. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology 2014; 59: 1435-1447.
[22] Anwanwan D, Singh SK, Singh S, Saikam V and Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer 2020; 1873: 188314.
[23] Luo M, Rehman A, Haque S, Izhar S, Perveen F, Haris M, Abdel-Maksoud MA, Saleh IA, Zomot N and Malik A. Thorough examination of the potential biological implications of the cuproptosis-related gene LIPT2 in the prognosis and immunotherapy in pan-cancer. American Journal of Translational Research 2024; 16: 940.
[24] Huang L, Irshad S, Sultana U, Ali S, Jamil A, Zubair A, Sultan R, Abdel-Maksoud MA, Mubarak A and Almunqedhi BM. Pan-cancer analysis of HS6ST2: associations with prognosis, tumor immunity, and drug resistance. American Journal of Translational Research 2024; 16: 873.
[25] Dias DC, Dolios G, Wang R and Pan ZQ. CUL7: A DOC domain-containing cullin selectively binds Skp1.Fbx29 to form an SCF-like complex. Proc Natl Acad Sci U S A 2002; 99: 16601-16606.
[26] Ali SH, Kasper JS, Arai T and DeCaprio JA. Cul7/p185/p193 binding to simian virus 40 large T antigen has a role in cellular transformation. J Virol 2004; 78: 2749-2757.
[27] Li Y, Zang A, Fu J and Jia Y. Cullin 7 in tumor development: a novel potential anti-cancer target. Neoplasma 2021; 68: 572-579.
[28] Wang H, Chen Y, Lin P, Li L, Zhou G, Liu G, Logsdon C, Jin J, Abbruzzese JL and Tan TH. The CUL7/F-box and WD repeat domain containing 8 (CUL7/Fbxw8) ubiquitin ligase promotes degradation of hematopoietic progenitor kinase 1. J Biol Chem 2014; 289: 4009-4017.
[29] Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B and Varambally S. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia 2017; 19: 649-658.
[30] Tang G, Cho M and Wang X. OncoDB: an interactive online database for analysis of gene expression and viral infection in cancer. Nucleic Acids Res 2022; 50: D1334-D1339.
[31] Maciejczyk A, Szelachowska J, Czapiga B, Matkowski R, Hałoń A, Györffy B and Surowiak P. Elevated BUBR1 expression is associated with poor survival in early breast cancer patients: 15-year follow-up analysis. J Histochem Cytochem 2013; 61: 330-339.
[32] Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C and Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-404.
[33] Shi L, Shang X, Nie K, Lin Z, Zheng M, Wang M, Yuan H and Zhu Z. Identification of potential crucial genes associated with the pathogenesis and prognosis of liver hepatocellular carcinoma. Journal of Clinical Pathology 2021; 74: 504-512.
[34] Kacar Z, Slud E, Levy D, Candia J, Budhu A, Forgues M, Wu X, Raziuddin A, Tran B and Shetty J. Characterization of tumor evolution by functional clonality and phylogenetics in hepatocellular carcinoma. Communications Biology 2024; 7: 383.
[35] Wang C, Zhao Z, Zhang Y, Liang W, Zhou C, Lin W, He Y, Wu M, Meng Z and Liao Y. Identification and verification of the prognostic value of CUL7 in colon adenocarcinoma. Frontiers in Immunology 2022; 13: 1043512.
[36] Xu J, Zhang Z, Qian M, Wang S, Qiu W, Chen Z, Sun Z, Xiong Y, Wang C and Sun X. Cullin-7 (CUL7) is overexpressed in glioma cells and promotes tumorigenesis via NF-κB activation. Journal of Experimental & Clinical Cancer Research 2020; 39: 1-21.
[37] Shi L, Du D, Peng Y, Liu J and Long J. The functional analysis of Cullin 7 E3 ubiquitin ligases in cancer. Oncogenesis 2020; 9: 98.
[38] Lee J and Zhou P. Cullins and cancer. Genes & cancer 2010; 1: 690-699.
[39] Hsu P-H, Ma Y-T, Fang Y-C, Huang J-J, Gan Y-L, Chang P-T, Jow G-M, Tang C-Y and Jeng C-J. Cullin 7 mediates proteasomal and lysosomal degradations of rat Eag1 potassium channels. Scientific Reports 2017; 7: 40825.
[40] Luo L, Su J, Zheng Y, Huang F, Huang R and Luo H. SLC2A5 correlated with immune infiltration: a candidate diagnostic and prognostic biomarker for lung adenocarcinoma. Journal of Immunology Research 2021; 2021:
[41] Tokheim C, Wang X, Timms RT, Zhang B, Mena EL, Wang B, Chen C, Ge J, Chu J and Zhang W. Systematic characterization of mutations altering protein degradation in human cancers. Molecular cell 2021; 81: 1292-1308. e1211.

Most read articles by the same author(s)